#Phase-3 trials

  • COVID-19 vaccine developed by China's CanSino to continue advancing phase-3 trials: report

    China's CanSino Biologics Inc. has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.

    The independent committee "found the drugmaker's COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," Reuters cited the biopharmaceutical company to report on Monday.

Partners